4-[2-(1-Methylethoxy)ethyl]piperidine | 70724-73-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[2-(1-Methylethoxy)ethyl]piperidine
• 英文别名: 4-(2-propan-2-yloxyethyl)piperidine
• CAS: 70724-73-1
• 化学式: C₁₀H₂₁NO
• 分子量: 171.28
• InChiKey: BEYQXDFWFKEGHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF<br/>[FR] INHIBITEURS D'ALK5, CONJUGUÉS ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2022006340A1

  公开（公告）日：2022-01-06

  ALK5 inhibitor compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. Additionally, compounds incorporated into a conjugate with an antibody construct are described herein.The disclosed compoundsand conjugates are useful, among other things, in the treating of cancer and fibrosis and modulating ALK5.

  本文披露了用于治疗疾病（如癌症）的ALK5抑制剂化合物、结合物和药物组合物。此外，本文还描述了与抗体构造物结合的化合物。所披露的化合物和结合物在治疗癌症和纤维化以及调节ALK5等方面非常有用。
• THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS
  申请人：White Stephen L.

  公开号：US20100216820A1

  公开（公告）日：2010-08-26

  The current invention provides compounds of formula (1): wherein: one of Q 1 , Q 2 and Q 3 is S, and the other of two of Q 1 , Q 2 and Q 3 are —CR 1 —, which are inhibitors of PI3K-delta. These compounds are useful for treatment of conditions mediated by PI3K-delta, such as hematopoietic cancers, immune disorders, and bone resorption disorders. The invention further provides pharmaceutical compositions comprising a compound of formula (1) and methods of using these compounds and compositions to treat conditions mediated by PI3K-delta.

  当前的发明提供了式（1）的化合物：其中：Q1、Q2和Q3中的一个是S，而Q1、Q2和Q3中的另外两个是—CR1—，这些化合物是PI3K-delta的抑制剂。这些化合物对于治疗由PI3K-delta介导的疾病，如造血系统癌症、免疫系统疾病和骨吸收障碍等，是有用的。该发明还提供了包含式（1）化合物的制药组合物以及使用这些化合物和组合物治疗由PI3K-delta介导的疾病的方法。
• AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1
  申请人：HOLCOMB Ryan C.

  公开号：US20120238540A1

  公开（公告）日：2012-09-20

  The invention relates to certain amino-pyrimidine compounds that inhibit IKK epsilon and/or TBK1, methods of making such compounds, pharmaceutical compositions comprising such compounds, and the use of these compounds in treating a variety of diseases and disorders.

  本发明涉及一些氨基嘧啶化合物，可抑制IKK epsilon和/或TBK1，制备这种化合物的方法，包含这种化合物的药物组合物，以及在治疗各种疾病和疾病失调中使用这些化合物的方法。
• Modulators of cystic fibrosis transmembrane conductance regulator
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10738030B2

  公开（公告）日：2020-08-11

  The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明公开了一种式 I 的化合物：或其药学上可接受的盐，其中 R1、R2、W、X、Z、n、p 和环 A 和环 B 在本文中定义，用于治疗 CFTR 介导的疾病，如囊性纤维化。本公开还包括药物组合物、治疗方法及其试剂盒。
• N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160280692A1

  公开（公告）日：2016-09-29

  Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.